High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia

Journal of Translational Medicine

Kai Hu¹  Jing Wang¹  Ping Yang¹  Weilong Zhang¹  Hongmei Jing¹  Xue He²  Xiuru Zhang²  Ying Song³  Xiaoliang Yuan⁴  Xiaoni Liu⁴  Weiyou Liu⁴ 

[1] 0000 0004 0605 3760, grid.411642.4, Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, 100191, Beijing, People’s Republic of China;0000 0004 0642 1244, grid.411617.4, Department of Pathology, Beijing Tiantan Hospital Affiliated With Capital Medical University, No. 6 Tiantan Xili, 100050, Beijing, China;0000 0004 1797 9454, grid.440714.2, The First Clinical College of Gannan Medical University, 341000, Ganzhou, China;grid.452437.3, Department of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, No. 23 Qingnian Road, Zhanggong District, 341000, Ganzhou, China;

关键词: NCALD;    Cytogenetic normal acute myeloid leukemia (CN-AML);    LSC;    Prognostic factor;   

DOI  :  10.1186/s12967-019-1904-5

来源: publisher

【 摘 要 】

BackgroundAcute myeloid leukemia (AML) is a heterogeneous disease in terms of genetic basis, clinical, biological and prognostic, and is a malignant clonal disease of leukemia stem cells (LSCs). Nearly half of adult AML patients exhibit a cytogenetic normal acute myeloid leukemia (CN-AML). The expression level of NCALD gene was associated with the prognosis of ovarian cancer and non-small cell lung cancer (NSCLC). The expression level of NCALD gene is still unclear in the prognosis of patients with AML.MethodWe integrated 5 independent datasets totally 665 AML patients (497 CN-AML patients) to analyzed relation between NCALD gene expression and the clinical FAB classification, gene mutation, therapy, prognosis of CN-AML. We analyzed the NCALD gene expression with the prognosis and LSC of 165 AML patients from The Cancer Genome Atlas (TCGA) dataset and 78 AML patients from GEO dataset.ResultsHigh NCALD-expressing CN-AML patients were associated with poor event-free survival (EFS) and overall survival (OS) compared to low NCALD expression (EFS, P < 0.0001, OS, P < 0.0001). In AML patients of allogeneic hematopoietic stem cell transplantation (allo-HSCT), high NCALD expression was associated with poor survival prognosis in EFS and OS (EFS, P < 0.0051, OS, P = 0.028). Post-chemotherapy in AML patients, high NCALD expression led a worse prognosis in EFS and OS (EFS, P = 0.011; OS, P = 0.0056). In multivariate analysis, high NCALD expression was an independent prognostic factor that predicts shorter EFS and OS (EFS, P = 3.84E−05, OS, P = 8.53E−05) of CN-AML.ConclusionOur results indicate that high expression of NCALD gene is a poor prognostic factor for CN-AML. NCALD can be considered as independent predictors of CN-AML patients and can be used as a biomarker for the prognosis of CN-AML.

【 授权许可】

CC BY